NOUL • Equipment and instruments for medical laboratories,Seoul

# Keyword
AI Digital Diagnostics, Microscope Automation, In Vitro Diagnostics (IVD), Healthcare Accessibility, Global Healthcare, Medical AI, Digital Healthcare, Medical Devices, Diagnostic Platform, Blood Testing

# Company Introduction
NOUL Co., Ltd., under the slogan Beyond Diagnostics, is a specialized medical device company that automates and standardizes blood, infectious disease, and cancer diagnostics through AIbased digital microscopy. Its mission is to enable hospitallevel diagnostics anywhere without skilled personnel or complex laboratory infrastructure, aiming to impact 1 billion lives by 2030. Recognized as an AI startup by NVIDIA GTC, NOUL entered a highgrowth phase in 2025 with 319% revenue growth and a 12fold increase in device sales.

# Main Product
The core product is miLab™ (DMLA/CCEA), an AIbased allinone digital microscopy diagnostic platform. It fully automates the process from smearing and staining to scanning and AI analysis using a singleuse cartridge. Featuring proprietary Next Generation Solidstate Staining (NGSI), it provides highquality results without washing or drying and is designed for PointofCare (POC) environments.

miLab™ MAL: AIbased malaria diagnostic solution with worldclass sensitivity
miLab™ BCM: Automated blood analysis (CBC and morphology) solution
miLab™ CER: AIbased cervical cancer screening solution

# Strength
Unique Technology: Combines liquidfree NGSI staining with machine learning to resolve labor intensity and low reproducibility in microscopy. Holds ISO 13485 and CE certifications.
Rapid Growth: 3x revenue growth and 12x device sales growth (2025). Expanding supply in Latin America and validated at global conferences like ESCMID and ASTMH.
Global Network: Operates a Swiss subsidiary (Noul GmbH) with clinical evaluations ongoing across Europe, the Middle East, Asia, and Africa.
Scalability: Pursuing strategic market entry in Germany, UK, France, Saudi Arabia, and Brazil.